PacBio bets on ‘inflection point’ with $500 long-read genomenews2024-10-29T17:20:46+00:00October 29th, 2024|Endpoints News|
Novartis highlights overall M&A track record following MorphoSys impairmentnews2024-10-29T17:02:34+00:00October 29th, 2024|Endpoints News|
In bid to lower ARIA-E, Eli Lilly tries a different dosing regimen for its Alzheimer’s drugnews2024-10-29T16:00:42+00:00October 29th, 2024|Endpoints News|
Vera’s $300M offering; Abeona resubmits treatment for rare skin diseasenews2024-10-29T14:50:05+00:00October 29th, 2024|Endpoints News|
Two type 1 diabetes patients are insulin-free after Eledon’s immunosuppressant and an islet transplantnews2024-10-29T14:49:50+00:00October 29th, 2024|Endpoints News|
GSK buys autoimmune T cell engager for $300M upfront from Chimagennews2024-10-29T14:48:34+00:00October 29th, 2024|Endpoints News|
Eyepoint sells $100M in shares after unveiling eye disease data for drug-device assetnews2024-10-29T14:38:51+00:00October 29th, 2024|Endpoints News|
GLP-1 compounding pharmacies took center stage at digital health’s biggest conferencenews2024-10-29T13:42:26+00:00October 29th, 2024|Endpoints News|
Pathos AI nabs $62M Series C as it hunts for more Phase 1 drugs with AInews2024-10-29T13:39:50+00:00October 29th, 2024|Endpoints News|
Paragon launches another company in hot PD-1xVEGF space that goes straight to reverse mergernews2024-10-29T11:33:53+00:00October 29th, 2024|Endpoints News|
